Aubrey de Grey began his career in artificial intelligence. His move into aging research came from a frustration he describes vividly: he had assumed scientists were working to solve aging, then concluded that much of the field was focused on understanding it instead. He wanted to approach the problem as a technologist.
That distinction shapes this conversation with Dr. Christian Mühlroth. De Grey presents aging through a damage-and-repair framework, describes experiments at the LEV Foundation, and argues that expectations about future lifespans could change society before the therapies themselves arrive.
His ambitions are substantial, and his forecasts are explicitly uncertain. For R&D leaders, the episode is valuable as a look at how a researcher breaks down a difficult problem, chooses an experimental milestone and tries to persuade others that it is worth pursuing. The proposed future is not an established medical outcome. It is the motivation behind a research program still being tested.
De Grey defines aging as two connected processes. In his account, the normal work of keeping a body alive creates molecular and cellular damage over time. Later, accumulated damage reaches levels that impair function.
His proposed response focuses on removing damage rather than reversing every process that produced it. To explain the distinction, he turns to a car. Rust is damage, but removing rust does not require running the chemical process of rusting backwards.
The analogy describes a research strategy; it does not demonstrate that a human body can be maintained like a vehicle. Its value is in making the proposed intervention clearer. Instead of asking how to stop every source of deterioration, de Grey asks which consequences might be repaired.
That shift matters beyond longevity. A technically difficult problem can look different when a team distinguishes the mechanism producing an unwanted effect from the effect it needs to address. The distinction gives researchers another set of hypotheses to test.
De Grey describes his approach as a divide-and-conquer strategy. He groups different forms of damage into categories so that work on one repair approach can inform related problems. But developing individual interventions is only part of the task. The next question is how they behave together.
In the episode, he describes a mouse study involving four interventions and multiple treatment groups, including groups receiving all or none of them. Treatment begins in middle age, after damage has accumulated but before the animals are already seriously unwell. The researchers monitor health as well as lifespan.
His account of the result is more restrained than the scale of his ambition might suggest. He reports an improvement, then explains why it falls short of the larger effect he wants to demonstrate. That gap becomes the reason for further experiments.
For a team combining technologies, this is an important distinction. Evidence that components have useful effects individually does not settle whether the combined approach is sufficiently comprehensive. Integration itself needs testing, with comparisons that make the contribution of the combination visible.
The conversation then turns to measurement. De Grey discusses biological-age indicators and the difficulty of interpreting them when a new therapy changes the system being measured.
A measure developed from existing observations may correlate with later outcomes. That does not, by itself, establish that it will reliably capture the effect of an intervention that was absent from those observations. He identifies this as a challenge for using such measures as substitutes for the outcomes researchers ultimately care about.
There is a direct R&D lesson here: a familiar metric may be useful without answering the new question. When an intervention changes the underlying conditions, the team needs to examine whether its measure still means what it used to mean.
The same care applies to translating results between settings. De Grey acknowledges that many findings in mice do not translate successfully to humans. He argues that his approach has better prospects, but that is his research expectation, not evidence that the translation has already succeeded.
De Grey believes researchers should discuss possible timelines rather than leave non-specialists to form expectations without expert input. He also stresses the uncertainty involved:
“Any prediction that one makes has to be probabilistic.”
His proposed timelines are his own estimates, accompanied in the interview by the possibility of much longer delays. They should be read as part of his argument about research priorities, not as a delivery schedule.
For innovation leaders, the useful tension is between communicating an ambition and overstating confidence. A forecast can help explain why a program deserves attention while still making room for unknown obstacles. Its purpose is to support decisions under uncertainty, not make the uncertainty disappear.
One of de Grey's most striking arguments concerns what could happen before a therapy becomes available. Insurance, pensions and inheritance decisions already depend on expectations about how long people will live. Convincing research results could change those expectations ahead of widespread treatment.
He calls this need to think ahead:
“Anticipate the anticipation.”
The wider social scenarios he discusses remain speculative. Yet the planning question is concrete: which decisions might customers, institutions or investors change if they became convinced that a major breakthrough was approaching?
The episode closes the distance between ambitious science and organizational preparation. Researchers need experiments that can test their claims. Leaders watching from outside need to distinguish emerging evidence from a compelling story, while recognizing that belief in the story can itself start changing behavior.